Latest news and press releases about Milestone Pharmaceuticals Inc. (MIST): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, specializing in the creation and commercialization of cardiovascular therapeutics. Their flagship product, etripamil, an innovative channel blocker, is currently in advanced clinical development.
Price
| Price | $0.89 |
| Market Cap | $111M |
| Exchange | NASDAQ |
| Country | CA |
Valuation Ratios
| Price / Book | 5.90 |
| EV / EBITDA | -2.60 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -150.97% |
| Return on Invested Capital | -62.00% |
| Return on Assets | -55.53% |
| Gross Margin | 94.58% |
| Operating Margin | -3353.01% |
| Net Margin | -3585.62% |
Related companies: APLT · CRBP · CRDF · CYBN · ELTX · IPHA · MOLN
Explore sector: Healthcare · Biotechnology
More sections of MIST: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks